Our Company
Generex Biotechnology has been engaged primarily in the research and development of drug delivery systems and technologies. Our primary focus has been our proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a handheld aerosol applicator.

Generex Biotechnology has a two business focuses: 1) implementing an acquisition strategy and 2) financing sponsored clinical trials. We are positioning ourselves as a diversified holding company involved in increasing our "pipeline" of compounds, therapies, treatments, diagnostics, and technologies in all stages in the FDA process through accretive acquisitions. We are also strategically aligning ourselves with the global biopharmaceutical companies by providing a financing solution to them as sponsors of clinical trials, which are conducted by patient care providers (PCPs) such as hospitals, medical research institutes, centers, and clinics.

​& Directors
Joseph Moscato - President & Chief Executive Officer
Mr. Moscato over 30 years of experience in healthcare, sales, marketing, and finance.

Mark Fletcher, Esq. - Company’s Executive Vice-President,
​General Counsel, and Secretary

Mr. Fletcher served as the Company’s President & Chief Executive Officer from September 2010 through January 2017 and as a member of the Board of Directors from March 2011 through January 2017.  He served as the Company’s Executive Vice-President and General Counsel from April 2003 through September 2010.   Prior to joining Generex, Mr. Fletcher was engaged in the private practice of corporate/commercial and securities law as a partner at Goodman and Carr LLP, a leading Toronto law firm.  Mr. Fletcher received his LL.B. from the University of Western Ontario and is a member of the Law Society of Upper Canada, the Canadian Bar Association, and the Association of Corporate Counsel.

Andrew Ro - Chief Investment Officer, Senior VP of Investments, Director
Mr. Ro over 20 years of experience in the financial markets. He is a partner with an investment fund.

Mark Corrao - Chief Financial Officer, Treasurer
Mr. Corrao over 20 years of experience in financial management. He is also involved in the initial registration of numerous public companies and subsequent SEC quarterly and annual reporting. He is a former CFO and a Director for a pharmaceutical company specializing in research and development, as well as novel and new therapeutic agents as immune modulators and neuroprotectants.

Jacob Dagan, Ph.D. - VP Business Development, Director
Dr. Dagan over 25 years of proven success in healthcare management, corporate and product development, operations, marketing, sales, and hospital management. He also has strong biomedical scientific skills.

Craig Eagle, MD - Director 
Dr. Eagle Head of Pfizer European, Head of Pfizer Canada, and Senior Director, Global Oncology Pfizer Global Pharmaceuticals.

Gary Lyman, MD, MPH -Director
Dr. Lyman is co-director of the Fred Hutchinson Institute for Cancer Outcomes Research, as well as Professor of Medicine and Professor in the Schools of Public Health & Pharmacy at the University of Washington.

Jason B. Terrell, MD - Director, Chief Medical and Scientific Officer
Dr. Terrell is currently Chief Medical Officer and Head of U.S. Operations for a NYSE-traded international medical diagnostic company.

Richard Purcell - Senior Vice President Research & New Drug Development, Director
Mr. Purcell is a consultant and advisor for emerging biopharmaceutical and technology companies on new business strategy, operations management, clinical development of novel compounds, data solutions for clinical and medical applications, and patient engagement and communication, as well as medical education for professionals, consumers, and data analytics for outcomes research.

Lawrence Salvo - Senior VP of Diagnostics, President of HDS, Director
Mr. Salvo is the founder of rapid diagnostic tests for infectious diseases. He is involved in the management of international distribution, sales, and design and has developed and maintained substantial and long-term relationships within China, South and Central America, and the African Continent.